Over the past decade, the emergence of effective immunotherapies has revolutionized the
clinical management of many types of cancers. However, long-term durable tumour control …

Background Clinical benefit of neoadjuvant immunotherapy in resectable esophageal
squamous cell carcinoma (ESCC). remains unclear. This study evaluated the efficacy and …

Background Predictive biomarkers could allow more precise use of immune checkpoint
inhibitors (ICIs) in treating advanced cancers. Given the central role of HLA molecules in …

The development of immune checkpoint inhibitors (ICIs) has a tremendous effect on the
treatment options for multiple types of cancer. Nonetheless, there is a large interpatient …

Introduction Biomarkers that predict the risk of immune-mediated adverse events (irAEs)
among patients with non-small cell lung cancer (NSCLC) may reduce morbidity and …

Introduction The magnitude of response to immune checkpoint inhibitor (ICI) therapy may be
sex-dependent, as females have lower response rates and decreased survival after ICI …

Immune checkpoint inhibitors (ICIs) have dramatically improved the outcomes of non-small
cell lung cancer patients and have increased the possibility of long-term survival. However …

Immune checkpoint inhibitors (ICIs) have revolutionised oncology and are now standard‐of‐
care for the treatment of a wide variety of solid neoplasms. However, tumour responses …

Abstract Background Neuroendocrine neoplasms (NENs) represent clinically and
genetically heterogeneous malignancies, thus a comprehensive understanding of …

Recombinant antibodies (Abs) are an integral modality for the treatment of multiple tumour
malignancies. Since the Food and Drug Administration (FDA) approval of rituximab as the …